Loading...
 

Volume 34, Issue 4, December 2023



Sign in to download the Issue in PDF format.

Mediterr J Rheumatol 2023;34(4):581-7
Comorbidities Burden and Implementation of the Treat–to–Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides
Authors Information
Rheumatology and Clinical Immunology, University of Crete Medical School and University Hospital of Iraklio, Iraklio, Greece

ID Flouri, G Bertsias, P Sidiropoulos
Abstract

New biologic and small molecule targeted agents have expanded the armamentarium of Spondyloarthritides (SpA), allowing more therapeutic options for patients who do not respond to therapy. The implementation of the treat-to-target (T2T) strategy with close monitoring and frequent treatment adaptations targeting disease remission has been proposed as the means to prevent radiographic progression and long-term adverse outcomes. In this project we will employ the “University of Crete Rheumatology Clinic Registry” to prospectively study in real-world practice musculoskeletal and extraarticular disease activity, patient function, comorbidities, sociodemographics, imaging, compliance to therapy and other lifestyle factors in axial and peripheral SpA patients. The predictive value of these variables in long-term (2years) outcomes will be evaluated. We will also assess the implementation of the T2T approach as well as its impact on long-term patients’ outcomes (quality of life, productivity, adverse events). The successful completion of this study could pave the way for improved and personalized therapy in patients with SpA.




https://doi.org/10.31138/mjr.310723.cba

Cite this article as: Flouri ID, Repa A, Avgoustidis M, Pitsigavdaki S, Pateromichelaki K, Marolachaki E, Terizaki M, Nikoloudaki M, Eskitzis A, Kalogiannaki E, Bertsias G, Sidiropoulos P. Comorbidities Burden and Implementation of the Treat–to–Target Strategy in Predicting Real-World Patient Outcomes in Spondyloarthritides. Mediterr J Rheumatol 2023;34(4):581-7

Article Submitted: 03 Feb 2023; Revised Form: 27 Apr 2023; Article Accepted: 15 May 2023; Available Online: 31 Jul 2023

This work is licensed under a Creative Commons Attribution 4.0 International License.

©2023 The Author(s).